A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell · Mesothelioma, Malignant · Prostatic Neoplasms, Castration-Resistant · Endometrial Cancer · Ovarian Clear Cell Carcinoma · Metastatic Castration-resistant Prostate Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

  • Emory University School of Medicine, Atlanta, Georgia, United States

    Contact: Principal Investigator (Jennifer Scalici, MD)
  • University of Chicago, Chicago, Illinois, United States

    Contact: Principal Investigator (Hedy L Kindler, MD)
  • Loyola University Medical Center, Maywood, Illinois, United States

  • University of Maryland Medical Ctr, Baltimore, Maryland, United States

  • Massachusetts General Hospital (MGH), Boston, Massachusetts, United States

    Contact: Principal Investigator (Ryan Sullivan, MD)
  • Dana Farber Cancer Institute (HARVARD), Boston, Massachusetts, United States

  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

  • Hackensack University Medical Center, Hackensack, New Jersey, United States

  • Roswell Park Cancer Institute, Buffalo, New York, United States

  • NYU Langone Medical Center, New York, New York, United States

  • Weill Medical College of Cornell University, New York, New York, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

  • University of Rochester Medical Center, Rochester, New York, United States

  • Montefiore Einstein Center for Cancer Care (MECCC), The Bronx, New York, United States

  • University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Principal Investigator (Lainie Martin, MD)
  • South Texas Accelerated Research Therapeutics (START) - San Antonio, San Antonio, Texas, United States

  • South Texas Accelerated Research Therapeutics (START) - Midwest Location, San Antonio, Texas, United States

  • University of Virginia Health System (UVAHS), Charlottesville, Virginia, United States

    Contact: Principal Investigator (Linda Duska, MD)
  • Swedish Cancer Institute, Seattle, Washington, United States

    Contact: Principal Investigator (Charles Drescher, MD)
  • Fred Hutchinson Cancer Center, Seattle, Washington, United States

    Contact: Principal Investigator (Kalyan Banda, MD)
  • CHU Bordeaux Hopital Saint Andre, Bordeaux, France

  • CLCC Institut Bergonie, Bordeaux, France

    Contact: Principal Investigator (Antoine Italiano)
  • Centre Oscar Lambret, Lille, France

    Contact: Principal Investigator (Cyril Abdeddaim)
  • Centre Leon Berard, Lyon, France

    Contact: Principal Investigator (Medhi Brahmi)
  • CHU Nantes Hopital Hotel Dieu, Nantes, France

    Contact: Principal Investigator (Caroline Viala)
  • CHU Nantes Hopital Hotel Dieu, Nantes, France

    Contact: Principal Investigator (Thomas Gastinne)
  • CHU Nantes Hopital Nord Laennec, Saint-Herblain, France

    Contact: Principal Investigator (Thomas Gastinne)
  • Institut Cancerologie de Strasbourg, Strasbourg, France

    Contact: Principal Investigator (Lauriane Eberst)
  • CLCC Institut Gustave Roussy, Villejuif, France

    Contact: Principal Investigator (Vincent Ribrag)
  • Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi, Bologna, Italy

  • Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy

  • National Cancer Institute, IRCCS, Milan, Italy

    Contact: Principal Investigator (Mara Mantiero)
  • European Institute of Oncology (IEO), IRCCS ( Department of Urogenital and Head-and-Neck Medical Oncology), Milan, Italy

    Contact: Principal Investigator (Franco Nole)
  • European Institute of Oncology (IEO), IRCCS, Milan, Italy

  • Humanitas San Pio X, Milan, Italy

    Contact: Principal Investigator (Domenica Lorusso)
  • IRCCS Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy

    Contact: Principal Investigator (Vanda Salutari)
  • IRCCS Istituto Clinico Humanitas - Research Hospital, Rozzano, Italy

    Contact: Principal Investigator (Carmelo Carlo-Stella)
  • Uniwersyteckie Centrum Kliniczne GUMed, Gdansk, Poland

    Contact: Principal Investigator (Rafal Dziadziuszko)
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Gliwice, Poland

  • Pratia MCM, Krakow, Poland

  • Institute of Polish Mother Health Centre - ICZMP, Lodz, Poland

  • Centrum Medyczne Pratia - Poznan, Poznan, Poland

  • University Teaching Hospital, Poznan, Poland

    Contact: Principal Investigator (Radoslaw Madry)
  • Novartis Investigative Site, Daegu, South Korea

  • National Cancer Center, Goyang-si Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center, Incheon, South Korea

    Contact: Principal Investigator (Kwang-Beom Lee)
  • Seoul National University Hospital, Seoul, South Korea

    Contact: Principal Investigator (Jae Weon Kim)
  • Yonsei Univ Health System YUCM, Seoul, South Korea

    Contact: Principal Investigator (Jung-Yun Lee)
  • Asan Medical Center, Seoul, South Korea

    Contact: Principal Investigator (Shinwha Lee)
  • Gangnam Severance Hospital, Seoul, South Korea

    Contact: Principal Investigator (Jae-Hoon Kim)
  • The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, South Korea

  • Hospital Vall d Hebron, Barcelona, Spain

    Contact: Principal Investigator (Ana Oaknin Benzaquen)
  • Hospital Clinic of Barcelona, Barcelona, Spain

    Contact: Principal Investigator (Begona Mellado Gonzalez)
  • Catalan Institute of Oncology, Barcelona, Spain

  • Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain

    Contact: Principal Investigator (Maria Pilar Barretina Ginesta)
  • University Hospital Ramon y Cajal, Madrid, Spain

    Contact: Principal Investigator (Teresa Alonso Gordoa)
  • University Hospital Clinical San Carlos, Department of Medical Oncology, Madrid, Spain

    Contact: Principal Investigator (Jorge Bartolome Arcilla)
  • University Hospital Foundation Jimenez Diaz, Madrid, Spain

    Contact: Principal Investigator (Bernard Gaston Doger De Speville Uribe)
  • Hospital Universitario 12 de Octubre, Madrid, Spain

  • Puerta de Hierro Majadahonda University Hospital, Majadahonda, Spain

    Contact: Principal Investigator (Aranzazu Gonzalez-Del-Alba)
  • Hospital Universitario Son Espases, Palma, Spain

    Contact: Principal Investigator (Jesus Alarcon Company)
  • Clinica Universidad de Navarra, Pamplona, Spain

  • Clinica Universidad de Navarra, Pamplona, Spain

    Contact: Principal Investigator (Antonio Jose Gonzalez Martin)
  • Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón, Spain

    Contact: Principal Investigator (Valentina Boni)
  • Parc Taulí Hospital Universitari, Sabadell, Spain

    Contact: Principal Investigator (Enrique Gallardo Diaz)
  • Hematology Department - Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain

  • Santiago Clinic Hospital CHUS, Santiago de Compostela, Spain

    Contact: Principal Investigator (Maria Teresa Curiel Garcia)
  • Hospital Virgen del Rocio, Seville, Spain

    Contact: Principal Investigator (Alejandro Falcon Gonzalez)
  • Instituto Valenciano de Oncologia, Valencia, Spain

    Contact: Principal Investigator (Ignacio Romero Noguera)
  • La Fe University and Polytechnic Hospital, Valencia, Spain

    Contact: Principal Investigator (Regina Girones Sarrio)
  • Royal United Hospital Bath NHS Trust, Bath, United Kingdom

  • Leicester General Hospital, Leicester, United Kingdom

    Contact: Principal Investigator (Harriet Walter)
  • Imperial College Healthcare NHS Trust, London, United Kingdom

  • The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Churchill Hospital, Oxford, United Kingdom

  • Southampton General Hospital, Southampton, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH), Sutton, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH), Sutton, United Kingdom

  • Musgrove Park Hospital, Taunton, United Kingdom

מובילי המחקר
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals